Cachexia is a complex, multifactorial, and multi-organ metabolic syndrome found in the late stages of serious illnesses including cancer, kidney disease, and congestive heart failure.
Author: Pharma Intelligence
Publisher: Datamonitor Healthcare
Published: 06 October 2022
Number of pages:26
This Market Spotlight report covers the Cachexia market, comprising epidemiology, key marketed and pipeline drugs, clinical trials, probability of success, and Licensing and Asset Acquisition Deals.
Adlumiz, an oral synthetic small molecule ghrelin mimetic, and Oxandrin, an orally active formulation of the anabolic steroid oxandrolone, are the only marketed drugs available for cachexia.
The majority of industry-sponsored drugs in active clinical development for cachexia are in Phase I, with only one drug in Phase III.
Therapies in active clinical development for cachexia focus on targets such as ghrelin receptor, growth differentiation factor 15, and GDNF receptor alpha-like (GFRAL). These drugs are administered via the oral and subcutaneous routes.
The overall likelihood of approval of a Phase I metabolic-other asset is 8.8%, and the average probability a drug advances from Phase III is 72.2%. Drugs, on average, take 9.0 years from Phase I to approval, compared to 9.6 years in the overall metabolic space.
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for cachexia have been in the early and midphases of development, with 78% of trials in Phase I–II, and only 22% in Phase III–IV.
The US has a substantial lead in the number of cachexia clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
Clinical trial activity in the cachexia space is dominated by completed trials. Helsinn has the highest number of completed clinical trials for cachexia, with eight trials.
Helsinn leads industry sponsors with the highest overall number of clinical trials for cachexia, followed by Ono Pharmaceutical and Pfizer
10 Cancer cachexia prevalence
10 Prevalence of cachexia due to other main causes
12 MARKETED DRUGS
14 PIPELINE DRUGS
18 PROBABILITY OF SUCCESS
19 LICENSING AND ASSET ACQUISITION DEALS
19 Yuhan Acquires Majority Stake In Microbiome-Focused AtoGen
20 CLINICAL TRIAL LANDSCAPE
21 Sponsors by status
22 Sponsors by phase
LIST OF FIGURES 14 Figure 1: Overview of pipeline drugs for cachexia in the US
14 Figure 2: Pipeline drugs for cachexia, by company
15 Figure 3: Pipeline drugs for cachexia, by drug type
15 Figure 4: Pipeline drugs for cachexia, by classification
18 Figure 5: Probability of success in the metabolic-other pipeline
20 Figure 6: Clinical trials in cachexia
20 Figure 7: Top 10 drugs for clinical trials in cachexia
21 Figure 8: Top 10 companies for clinical trials in cachexia
21 Figure 9: Trial locations in cachexia
22 Figure 10: Cachexia trials status
23 Figure 11: Cachexia trials sponsors, by phase
LIST OF TABLES
9 Table 1: Drugs used for the treatment of cachexia
13 Table 2: Marketed drugs for cachexia
16 Table 3: Pipeline drugs for cachexia in the US
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.